Topical antineoplastic agents in the treatment of mucocutaneous diseases

Anna L Grossberg, Anthony A. Gaspari

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Topical antineoplastic agents have a well- established role in the treatment of several dermatological conditions. Their use in the treatment of mucosal skin disease also has gained increasing recognition. Topical 5- fluorouracil (5- FU), an antimetabolite, and imiquimod, an immunomodulatory agent with antitumor properties, are the two principal topical antineoplastic agents used in the treatment of mucocutaneous diseases. Although the vast majority of their mucosal uses are currently not approved by the Federal Drug Administration, there are numerous case series, open- label studies and randomized controlled trials supporting their uses in the treatment of mucocutaneous diseases. Both topical 5- FU and imiquimod have been successfully utilized in the treatment of a wide range of mucosal diseases, including actinic cheilitis, Bowen's disease of the anal and vulvar mucosa, and genital and perianal condyloma. Reports of their uses in the treatment of mucocutaneous diseases indicate that these agents can be safely administered, though adverse effects such as local inflammation may be augmented when these agents are applied to mucosal surfaces. Additionally, locally acting intralesional chemotherapeutic agents, such as bleomycin and interferon, have well- defined applications in the treatment of mucosal skin diseases such as condyloma acuminata. As further studies are conducted, these topical and intralesional neoplastic agents, in addition to emerging agents that are in various stages of development, such as Tolllike receptor 9 agonists and ingenol mebutate, may play an increasingly important role in the future treatment of mucocutaneous diseases.

Original languageEnglish (US)
Title of host publicationTopical Applications and the Mucosa
PublisherS. Karger AG
Pages71-82
Number of pages12
Volume40
ISBN (Print)9783805596169, 9783805596152
DOIs
StatePublished - Feb 10 2011
Externally publishedYes

Fingerprint

Antineoplastic Agents
imiquimod
Skin Diseases
Fluorouracil
Bowen's Disease
Antimetabolites
Condylomata Acuminata
Bleomycin
Interferons
Mucous Membrane
Randomized Controlled Trials
Inflammation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Grossberg, A. L., & Gaspari, A. A. (2011). Topical antineoplastic agents in the treatment of mucocutaneous diseases. In Topical Applications and the Mucosa (Vol. 40, pp. 71-82). S. Karger AG. https://doi.org/10.1159/000321056

Topical antineoplastic agents in the treatment of mucocutaneous diseases. / Grossberg, Anna L; Gaspari, Anthony A.

Topical Applications and the Mucosa. Vol. 40 S. Karger AG, 2011. p. 71-82.

Research output: Chapter in Book/Report/Conference proceedingChapter

Grossberg, AL & Gaspari, AA 2011, Topical antineoplastic agents in the treatment of mucocutaneous diseases. in Topical Applications and the Mucosa. vol. 40, S. Karger AG, pp. 71-82. https://doi.org/10.1159/000321056
Grossberg AL, Gaspari AA. Topical antineoplastic agents in the treatment of mucocutaneous diseases. In Topical Applications and the Mucosa. Vol. 40. S. Karger AG. 2011. p. 71-82 https://doi.org/10.1159/000321056
Grossberg, Anna L ; Gaspari, Anthony A. / Topical antineoplastic agents in the treatment of mucocutaneous diseases. Topical Applications and the Mucosa. Vol. 40 S. Karger AG, 2011. pp. 71-82
@inbook{f919947b4ccb44faa0a3da6271eb9a39,
title = "Topical antineoplastic agents in the treatment of mucocutaneous diseases",
abstract = "Topical antineoplastic agents have a well- established role in the treatment of several dermatological conditions. Their use in the treatment of mucosal skin disease also has gained increasing recognition. Topical 5- fluorouracil (5- FU), an antimetabolite, and imiquimod, an immunomodulatory agent with antitumor properties, are the two principal topical antineoplastic agents used in the treatment of mucocutaneous diseases. Although the vast majority of their mucosal uses are currently not approved by the Federal Drug Administration, there are numerous case series, open- label studies and randomized controlled trials supporting their uses in the treatment of mucocutaneous diseases. Both topical 5- FU and imiquimod have been successfully utilized in the treatment of a wide range of mucosal diseases, including actinic cheilitis, Bowen's disease of the anal and vulvar mucosa, and genital and perianal condyloma. Reports of their uses in the treatment of mucocutaneous diseases indicate that these agents can be safely administered, though adverse effects such as local inflammation may be augmented when these agents are applied to mucosal surfaces. Additionally, locally acting intralesional chemotherapeutic agents, such as bleomycin and interferon, have well- defined applications in the treatment of mucosal skin diseases such as condyloma acuminata. As further studies are conducted, these topical and intralesional neoplastic agents, in addition to emerging agents that are in various stages of development, such as Tolllike receptor 9 agonists and ingenol mebutate, may play an increasingly important role in the future treatment of mucocutaneous diseases.",
author = "Grossberg, {Anna L} and Gaspari, {Anthony A.}",
year = "2011",
month = "2",
day = "10",
doi = "10.1159/000321056",
language = "English (US)",
isbn = "9783805596169",
volume = "40",
pages = "71--82",
booktitle = "Topical Applications and the Mucosa",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Topical antineoplastic agents in the treatment of mucocutaneous diseases

AU - Grossberg, Anna L

AU - Gaspari, Anthony A.

PY - 2011/2/10

Y1 - 2011/2/10

N2 - Topical antineoplastic agents have a well- established role in the treatment of several dermatological conditions. Their use in the treatment of mucosal skin disease also has gained increasing recognition. Topical 5- fluorouracil (5- FU), an antimetabolite, and imiquimod, an immunomodulatory agent with antitumor properties, are the two principal topical antineoplastic agents used in the treatment of mucocutaneous diseases. Although the vast majority of their mucosal uses are currently not approved by the Federal Drug Administration, there are numerous case series, open- label studies and randomized controlled trials supporting their uses in the treatment of mucocutaneous diseases. Both topical 5- FU and imiquimod have been successfully utilized in the treatment of a wide range of mucosal diseases, including actinic cheilitis, Bowen's disease of the anal and vulvar mucosa, and genital and perianal condyloma. Reports of their uses in the treatment of mucocutaneous diseases indicate that these agents can be safely administered, though adverse effects such as local inflammation may be augmented when these agents are applied to mucosal surfaces. Additionally, locally acting intralesional chemotherapeutic agents, such as bleomycin and interferon, have well- defined applications in the treatment of mucosal skin diseases such as condyloma acuminata. As further studies are conducted, these topical and intralesional neoplastic agents, in addition to emerging agents that are in various stages of development, such as Tolllike receptor 9 agonists and ingenol mebutate, may play an increasingly important role in the future treatment of mucocutaneous diseases.

AB - Topical antineoplastic agents have a well- established role in the treatment of several dermatological conditions. Their use in the treatment of mucosal skin disease also has gained increasing recognition. Topical 5- fluorouracil (5- FU), an antimetabolite, and imiquimod, an immunomodulatory agent with antitumor properties, are the two principal topical antineoplastic agents used in the treatment of mucocutaneous diseases. Although the vast majority of their mucosal uses are currently not approved by the Federal Drug Administration, there are numerous case series, open- label studies and randomized controlled trials supporting their uses in the treatment of mucocutaneous diseases. Both topical 5- FU and imiquimod have been successfully utilized in the treatment of a wide range of mucosal diseases, including actinic cheilitis, Bowen's disease of the anal and vulvar mucosa, and genital and perianal condyloma. Reports of their uses in the treatment of mucocutaneous diseases indicate that these agents can be safely administered, though adverse effects such as local inflammation may be augmented when these agents are applied to mucosal surfaces. Additionally, locally acting intralesional chemotherapeutic agents, such as bleomycin and interferon, have well- defined applications in the treatment of mucosal skin diseases such as condyloma acuminata. As further studies are conducted, these topical and intralesional neoplastic agents, in addition to emerging agents that are in various stages of development, such as Tolllike receptor 9 agonists and ingenol mebutate, may play an increasingly important role in the future treatment of mucocutaneous diseases.

UR - http://www.scopus.com/inward/record.url?scp=84925954065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925954065&partnerID=8YFLogxK

U2 - 10.1159/000321056

DO - 10.1159/000321056

M3 - Chapter

C2 - 21325841

AN - SCOPUS:79951713205

SN - 9783805596169

SN - 9783805596152

VL - 40

SP - 71

EP - 82

BT - Topical Applications and the Mucosa

PB - S. Karger AG

ER -